On the Horizon
Please join us for a discussion about where we’ve been and where we’re going with respect to treatments and therapies for bleeding disorders. This session will be presented as a panel discussion. Each panelist will present information on topics such as our history, current treatments, and emerging treatments. The audience will have an opportunity to have questions answered during the On the Horizon Q and A on Friday, April 23, from 1:45-2:45 PM.
Allison Wheeler, MD, MSCI
Originally from Boston MA, Allison Wheeler received her medical training at the University of Massachusetts. She subsequently completed her Pediatric hematology / oncology and blood banking / transfusion medicine fellow training at Vanderbilt University Medical Center. She has worked at faculty in pediatrics and pathology at Vanderbilt since the completion of her training in 2014, which represented a surprising and seemingly permanent move to Tennessee. Allison splits her clinical time between pediatric patients with hemostatic and thrombotic disorders, and aids in management of both the transfusion medicine and coagulation services. She is also the director of research for benign hematology with a robust collaborative research portfolio and a personal research interest in women with heavy menstrual bleeding. She has recently been involved with research focused on the use of convalescent plasma to treat COVID-19, as well as work in vaccine safety due to hematologic concerns associated with the COVID-19 vaccines. Allison spends as much time outside as she can when she isn’t at work, she loves running and hiking, and her family – husband Scott and 3 kids (Finn (18), Darby (15) and Nat (3).
David Clark, PhD
Dr. Clark is an independent consultant to the biotechnology, plasma and tissue industries. He is the President of Platte Canyon Consulting, Inc. and the Chairman of the Coalition for Hemophilia B. He spent 19+ years working for the American Red Cross on the development of plasma-derived and recombinant plasma protein products, including Factors VIII and IX. He writes articles on current research for the Coalition newsletter, Factor IX News. He has a Ph.D. in chemical engineering from Cornell University.
Robert Sidonio, MD, MSc
Dr. Sidonio’s interest in hemostasis began during his pediatric residency at the University of Louisville under the mentorship of Dr. Sanjay Ahuja. Subsequently under Dr. Margaret Ragni’s research guidance during his fellowship he was accepted to the ASH Clinical Research Training Institute (CRTI) in 2009. Following fellowship at the University of Pittsburgh, he took a position as Director of Pediatric Hemostasis and Thrombosis Program at Vanderbilt University. Under Dr. Michael DeBaun’s mentorship he was able to obtain to obtain a KL2 to investigate the bleeding tendency in hemophilia A carriers. In August 2014, Dr. Sidonio accepted the position of Associate Director of Hemostasis and Thrombosis at Emory University/Children’s Healthcare of Atlanta. Dr. Sidonio is continuing his clinical research investigating the bleeding phenotype and genotype of hemophilia A carriers funded by the Hemophilia of Georgia Clinical Scientist Development Grant and HTRS Mentored Research Award.